$NBIX News

Neurocrine Biosciences: 'House Full Of Options'

Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?

Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?

NBIX Stock Dips 12% in a Month: Time to Buy, Hold or Sell?

Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Lowers Price Target to $182

NBIX Stock Slips As $2.9B Soleno Deal Triggers Fresh Drug Safety Warnings

Neurocrine Biosciences shares fall amid Vykat safety concerns

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences Announces Publication Of Its KINCET-PRO Phase 4 Study Results Showing That Once-Daily INGREZZA Capsules Led To Substantial And Sustained Improvements In Patient-Reported Quality Of Life And Functionality

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation

Neurocrine Biosciences Initiates Phase 1 First-In-Human Clinical Study Evaluating NBIP-'1968, Investigational GLP-1/GIP/Glucagon Receptor Triple Agonist Being Developed As Therapy For Obesity

Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount

Neurocrine (NBIX) Q2 2026 Earnings Call Transcript

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Raises Price Target to $210

Truist Securities Maintains Buy on Neurocrine Biosciences, Raises Price Target to $213

Wedbush Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $194

Neurocrine Biosciences (NBIX) Is Down 5.1% After Q2 Earnings Beat And Higher INGREZZA Guidance – What's Changed

Neurocrine Biosciences (NBIX) Appoints Four Senior Leaders As Pipeline And Portfolio Expand

Neurocrine Biosciences (NBIX) Lifts INGREZZA Guidance, Is The Pullback A Bargain?